Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

J&J taps TARIS Biomedical for novel bladder cancer technology

Takes a bigger stake in the bladder cancer market

- PMLiVE

FDA rejects ViiV’s long-acting monthly HIV injection

Blow to company as it hopes to capture market share from Gilead

- PMLiVE

Takeda’s subcutaneous Entyvio formulation faces FDA rejection

Was seeking approval in moderate-to-severe ulcerative colitis

- PMLiVE

The mission matters

The mission statement is more than a platitude

- PMLiVE

AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu

Early approval comes well ahead of schedule

Roche Basel Switzerland

Roche pays $1.15bn for Sarepta’s Duchenne gene therapy

Pens another gene therapy deal following takeover of Spark Therapeutics

- PMLiVE

Biogen bets on Ionis’ early-stage Alzheimer’s drug

Paid $45m upfront with potential milestones of up to $155m

- PMLiVE

FDA follows EMA with approval of Merck’s Ebola vaccine

First to be approved in the US

- PMLiVE

Low-dose LSD looks safe for Alzheimer’s patients, but will it work?

Biotech Eleusis completes promising phase 1 trial

- PMLiVE

J&J gets EU approval for depression nasal spray Spravato

Approved with a risk management plan to guard dosing

- PMLiVE

It’s been altogether more magic for Lucid Group in 2019

As Lucid closes its doors to 2019, there's a lot to be proud of.2019 has been a landmark year for the Group as they embarked on ambitious growth plans which...

Lucid Group Communications Limited

2019: A pivotal year for the NHS

Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the key changes in the NHS in 2019

Wilmington Healthcare

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links